Skip to main content

FDA clears IND for SBC003 in RPRead more

SunRegen Healthcare home

Get in Touch

Contact

Two offices, one mission: for science, partnerships, investment, or careers.

Series A Open

Series A Investment Inquiries

SunRegen is executing a strategic Series A financing round targeting $35M+ to fund Phase I/II clinical trials in Retinitis Pigmentosa.

We actively invite rigorous inquiries from venture capital syndicates, institutional life science funds, and strategic pharmaceutical partners.

Open conversation
Company: SunRegen Healthcare AGUID: CHE-295.245.274Registered in Switzerland